JP2008503573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008503573A5 JP2008503573A5 JP2007518002A JP2007518002A JP2008503573A5 JP 2008503573 A5 JP2008503573 A5 JP 2008503573A5 JP 2007518002 A JP2007518002 A JP 2007518002A JP 2007518002 A JP2007518002 A JP 2007518002A JP 2008503573 A5 JP2008503573 A5 JP 2008503573A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally
- alkoxy
- phenyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 336
- 125000003545 alkoxy group Chemical group 0.000 claims description 55
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- -1 CF 3 Chemical group 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 21
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 10
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 10
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 7
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 125000004434 sulfur atom Chemical group 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000003386 piperidinyl group Chemical group 0.000 claims description 5
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 101100294116 Caenorhabditis elegans nhr-51 gene Proteins 0.000 claims 1
- 101100294120 Caenorhabditis elegans nhr-55 gene Proteins 0.000 claims 1
- 101100294121 Caenorhabditis elegans nhr-57 gene Proteins 0.000 claims 1
- 101100516553 Caenorhabditis elegans nhr-59 gene Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 238000006268 reductive amination reaction Methods 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- UCGQUQXNDQURCO-UHFFFAOYSA-N tert-butyl 4-fluoro-4-[2-(4-methylsulfonylphenyl)sulfonylethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(F)CCS(=O)(=O)C1=CC=C(S(C)(=O)=O)C=C1 UCGQUQXNDQURCO-UHFFFAOYSA-N 0.000 description 1
- ZJVSMCROBRXRRX-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-[2-(4-methylsulfonylphenyl)sulfonylethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(O)CCS(=O)(=O)C1=CC=C(S(C)(=O)=O)C=C1 ZJVSMCROBRXRRX-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0401656A SE0401656D0 (sv) | 2004-06-24 | 2004-06-24 | Chemical compounds |
| PCT/SE2005/000953 WO2006001752A1 (en) | 2004-06-24 | 2005-06-20 | Novel piperidine/8-azabicyclo [3.2.1] octan derivatives as moduilators of chemokine receptor ccr5 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008503573A JP2008503573A (ja) | 2008-02-07 |
| JP2008503573A5 true JP2008503573A5 (enExample) | 2008-07-31 |
Family
ID=32733686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518002A Pending JP2008503573A (ja) | 2004-06-24 | 2005-06-20 | ケモカイン・レセプターｃｃｒ５のモジュレーターとしての新規ピペリジン／８−アザビシクロ［３．２．１］オクタン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080021038A1 (enExample) |
| EP (1) | EP1761491A1 (enExample) |
| JP (1) | JP2008503573A (enExample) |
| CN (1) | CN101006057A (enExample) |
| AR (1) | AR049834A1 (enExample) |
| AU (1) | AU2005257708A1 (enExample) |
| CA (1) | CA2570893A1 (enExample) |
| IL (1) | IL179733A0 (enExample) |
| MX (1) | MXPA06014412A (enExample) |
| SE (1) | SE0401656D0 (enExample) |
| WO (1) | WO2006001752A1 (enExample) |
| ZA (1) | ZA200610430B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200610761A (en) * | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| WO2009010478A2 (en) * | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Use of piperidine derivatives as agonists of chemokine receptor activity |
| WO2009010479A2 (en) * | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| FR2938537B1 (fr) | 2008-11-14 | 2012-10-26 | Sanofi Aventis | Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique. |
| US8217060B2 (en) | 2009-05-15 | 2012-07-10 | Janssen Pharmaceutica, Nv | Benzimidazole derivatives useful as TRP M8 receptor modulators |
| EP2741777B1 (en) * | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| WO2016100823A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| US10633336B2 (en) | 2014-12-19 | 2020-04-28 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
| KR20200112910A (ko) | 2018-01-26 | 2020-10-05 | 시오노기 앤드 컴파니, 리미티드 | 도파민 d3 수용체 길항 작용을 갖는 축환 화합물 |
| AU2021222441A1 (en) | 2020-02-19 | 2022-09-22 | Ichilov Tech Ltd. | Improved antidepressant therapy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE775611A (fr) * | 1970-11-24 | 1972-03-16 | Synthelabo | Derives de la (diphenyl-3,3 propyl-1)-1 piperidine, leur preparation etles medicaments qui en contiennent |
| JPS5742671A (en) * | 1980-08-20 | 1982-03-10 | Janssen Pharmaceutica Nv | Manufacture of 4-(4-chlorophenyl)-4-hydroxy- n,n-dimethyl-alpha,alpha-diphenyl-1- piperidine butaneamide |
| IE912759A1 (en) * | 1990-08-06 | 1992-02-12 | Smith Kline French Lab | Compounds |
| JPH08337569A (ja) * | 1995-06-15 | 1996-12-24 | Sankyo Co Ltd | 鎮痛活性物質 |
| GB9523526D0 (en) * | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
| ID24475A (id) * | 1997-11-18 | 2000-07-20 | Teijin Limeted Cs | Turunan-turunan amina siklik dan penggunaannya sebagai obat |
| US6288083B1 (en) * | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US7217714B1 (en) * | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| WO2000076514A1 (en) * | 1999-06-11 | 2000-12-21 | Merck & Co., Inc. | Cyclopentyl modulators of chemokine receptor activity |
| GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| US6511994B2 (en) * | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
| JP2004520423A (ja) * | 2001-03-01 | 2004-07-08 | アストラゼネカ・アクチエボラーグ | Ｃｃｒ５モジュレーターとしてのｎ−ピペリジニル化合物 |
| GB0108046D0 (en) * | 2001-03-30 | 2001-05-23 | Astrazeneca Ab | Chemical compounds |
| SE0103819D0 (sv) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| SE0103818D0 (sv) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| US7202259B2 (en) * | 2002-11-18 | 2007-04-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| SE0203828D0 (sv) * | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | Chemical compounds |
| SE0203820D0 (sv) * | 2002-12-20 | 2002-12-20 | Astrazeneca Ab | chemical compounds |
| AR042628A1 (es) * | 2002-12-20 | 2005-06-29 | Astrazeneca Ab | Derivados de piperidina como moduladores del receptor ccr5 |
-
2004
- 2004-06-24 SE SE0401656A patent/SE0401656D0/xx unknown
-
2005
- 2005-06-20 JP JP2007518002A patent/JP2008503573A/ja active Pending
- 2005-06-20 CN CNA2005800284322A patent/CN101006057A/zh active Pending
- 2005-06-20 EP EP05754141A patent/EP1761491A1/en not_active Withdrawn
- 2005-06-20 US US11/628,808 patent/US20080021038A1/en not_active Abandoned
- 2005-06-20 CA CA002570893A patent/CA2570893A1/en not_active Abandoned
- 2005-06-20 MX MXPA06014412A patent/MXPA06014412A/es not_active Application Discontinuation
- 2005-06-20 AU AU2005257708A patent/AU2005257708A1/en not_active Abandoned
- 2005-06-20 WO PCT/SE2005/000953 patent/WO2006001752A1/en not_active Ceased
- 2005-06-24 AR ARP050102619A patent/AR049834A1/es unknown
-
2006
- 2006-11-30 IL IL179733A patent/IL179733A0/en unknown
- 2006-12-12 ZA ZA200610430A patent/ZA200610430B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008503573A5 (enExample) | ||
| EP2632551B1 (en) | Soluble guanylate cyclase activators | |
| TWI613193B (zh) | 包含磺醯亞胺基團之５－氟－ｎ－（吡啶－２－基）吡啶－２－胺衍生物 | |
| JP2019094350A (ja) | 抗癌活性及び抗増殖活性を呈する２−アミノピリミジン−６−オン及び類似体 | |
| US12351582B2 (en) | Aurora kinase inhibitors and uses thereof | |
| JP2008526724A5 (enExample) | ||
| JP2005509622A5 (enExample) | ||
| WO2016089060A2 (en) | Heterocyclic derivatives and use thereof | |
| JP2011520896A5 (enExample) | ||
| EP3094627A1 (en) | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 | |
| AR041055A1 (es) | Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto | |
| MXPA04003610A (es) | Analogos de himbacina como antagonistas del receptor de trombina. | |
| JP2007501831A5 (enExample) | ||
| WO2014145029A2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2011526917A5 (enExample) | ||
| KR20210049858A (ko) | Jak 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리딘 화합물 및 이의 용도 | |
| JP2011116795A (ja) | 置換５−アミノ−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ［１，５−ｃ］ピリミジンを調製するためのプロセス | |
| JP2013526610A5 (enExample) | ||
| US20190202826A1 (en) | Phosphotidylinositol 3-Kinase Inhibitors | |
| WO2020088390A1 (zh) | 作为第四代egfr抑制剂的嘧啶吡唑类化合物 | |
| JP2020533319A (ja) | シクロオレフィン置換複素芳香族化合物およびそれらの使用 | |
| CA2534003A1 (en) | 3-quinuclidinyl-n-biarylamides as nicotinic acetylcholine receptor agonists | |
| JP2007500694A5 (enExample) | ||
| WO2006111662A3 (fr) | Derives de 4h-1 , 2 , 4-triazin-5-0nes , leur preparation et leur utilisation comme des recepteurs a l'acetylcholine de type nicotiniques alpha7 | |
| RU2008129364A (ru) | Новые циклически замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний |